- Home
- NDLS vs INKT Comparison
NDLS vs INKT Comparison
Compare NDLS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDLS | INKT |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 57.6M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NDLS | INKT |
|---|---|---|
| Price | $6.11 | $9.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 104.0K | ★ 141.0K |
| Earning Date | 04-09-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $493,271,000.00 | N/A |
| Revenue This Year | $2.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $6.66 |
| 52 Week High | $7.09 | $76.00 |
Technical Indicators
Market Signals| Indicator | NDLS | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 79.68 | 42.47 |
| Support Level | $0.62 | $6.80 |
| Resistance Level | $7.09 | $12.97 |
| Average True Range (ATR) | 0.46 | 0.58 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 48.95 | 9.36 |
Price Performance
Historical ComparisonAbout NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.